Citius Pharmaceuticals (CTXR) 10-Q 13 Feb 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Dec. 31, 2019	Feb. 07, 2020
Document and Entity Information [Abstract]
Entity Registrant Name	Citius Pharmaceuticals, Inc.
Entity Central Index Key	0001506251
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Document Type	10-Q
Document Period End Date	Dec. 31, 2019
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		31,493,389
Entity File Number	001-38174
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	NV

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Dec. 31, 2019	Sep. 30, 2019
Current Assets:
Cash and cash equivalents	$ 2,779,650	$ 7,893,804
Prepaid expenses	55,747	48,111
Total Current Assets	2,835,397	7,941,915
Property and equipment, net	413	590
Operating lease right-of-use asset, net	1,103,155
Other Assets:
Deposits	57,093	57,093
In-process research and development	19,400,000	19,400,000
Goodwill	1,586,796	1,586,796
Total Other Assets	21,043,889	21,043,889
Total Assets	24,982,854	28,986,394
Current Liabilities:
Accounts payable	1,547,261	2,713,542
Accrued expenses	209,118	246,225
Accrued compensation	1,475,983	1,400,688
Accrued interest - related parties	78,288	74,297
Notes payable - related parties	172,970	172,970
Operating lease liability	146,244
Total Current Liabilities	3,629,864	4,607,722
Operating lease liability - non current	976,198
Total Liabilities	4,606,062	4,607,722
Commitments and Contingencies
Stockholders' Equity:
Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock - $0.001 par value; 200,000,000 shares authorized; 30,177,674 and 28,930,493 shares issued and outstanding at December 31, 2019 and September 30, 2019, respectively	30,178	28,930
Additional paid-in capital	80,488,966	80,169,724
Accumulated deficit	(60,142,352)	(55,819,982)
Total Stockholders' Equity	20,376,792	24,378,672
Total Liabilities and Stockholders' Equity	$ 24,982,854	$ 28,986,394

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Dec. 31, 2019	Sep. 30, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	30,177,674	28,930,493
Common stock, shares outstanding	30,177,674	28,930,493

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Statement [Abstract]
Revenues
Operating Expenses
Research and development	2,664,546	2,113,101
General and administrative	1,562,995	1,588,124
Stock-based compensation - general and administrative	220,384	171,249
Total Operating Expenses	4,447,925	3,872,474
Operating Loss	(4,447,925)	(3,872,474)
Other Income (Expense)
Other income	110,207
Interest income	19,339	1,747
Interest expense	(3,991)	(4,003)
Total Other Income (Expense), Net	125,555	(2,256)
Net Loss	$ (4,322,370)	$ (3,874,730)
Net Loss Per Share - Basic and Diluted	$ (0.15)	$ (0.22)
Weighted Average Common Shares Outstanding
Basic and diluted	29,197,980	17,764,008

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Sep. 30, 2018		$ 16,199	$ 68,107,323	$ (40,257,838)
Balance, shares at Sep. 30, 2018		16,198,791
Issuance of common stock upon exercise of warrants		$ 1,600	14,400		$ 16,000
Issuance of common stock upon exercise of warrants, shares		1,600,000
Stock-based compensation expense			171,249		171,249
Net loss				(3,874,730)	(3,874,730)
Balance at Dec. 31, 2018		$ 17,799	68,292,972	(44,132,568)	24,178,203
Balance, shares at Dec. 31, 2018		17,798,791
Balance at Sep. 30, 2019		$ 28,930	80,169,724	(55,819,982)	24,378,672
Balance, shares at Sep. 30, 2019		28,930,493
Issuance of common stock upon exercise of warrants		$ 1,061	(955)		106
Issuance of common stock upon exercise of warrants, shares		1,060,615
Issuance of common stock for services		$ 187	99,813		100,000
Issuance of common stock for services, shares		186,566
Stock-based compensation expense			220,384		220,384
Net loss				(4,322,370)	(4,322,370)
Balance at Dec. 31, 2019		$ 30,178	$ 80,488,966	$ (60,142,352)	$ 20,376,792
Balance, shares at Dec. 31, 2019		30,177,674

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash Flows From Operating Activities:
Net loss	$ (4,322,370)	$ (3,874,730)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	220,384	171,249
Issuance of common stock for services	100,000
Amortization of operating lease right-of-use asset	34,569
Depreciation	177	235
Changes in operating assets and liabilities:
Other receivables		818,343
Prepaid expenses	(7,636)	11,109
Accounts payable	(1,166,281)	509,988
Accrued expenses	(37,107)	18,773
Accrued compensation	75,295	182,500
Accrued interest - related parties	3,991	4,003
Operating lease liability	(15,282)
Net Cash Used In Operating Activities	(5,114,260)	(2,158,530)
Cash Flows From Financing Activities:
Proceeds from common stock warrant exercises	106	16,000
Net Cash Provided By Financing Activities	106	16,000
Net Change in Cash and Cash Equivalents	(5,114,154)	(2,142,530)
Cash and Cash Equivalents - Beginning of Period	7,893,804	9,184,003
Cash and Cash Equivalents - End of Period	2,779,650	7,041,473
Supplemental Disclosures Of Cash Flow Information and Non-cash Activities:
Operating lease right-of-use asset and liability recorded upon adoption of ASC 842	$ 1,137,724

Nature of Operations, Basis of

Nature of Operations, Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	1. NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business Citius Pharmaceuticals, Inc. ("Citius" or the "Company") is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting important medical needs with a focus on anti-infective products in adjunct cancer care and unique prescription products. On March 30, 2016, Citius acquired Leonard-Meron Biosciences, Inc. ("LMB") as a wholly-owned subsidiary. The Company acquired all of the outstanding stock of LMB by issuing shares of its common stock. The net assets acquired included identifiable intangible assets of $19,400,000 related to in-process research and development. The Company recorded goodwill of $1,586,796 for the excess of the purchase price over the net assets. In-process research and development represents the value of LMB's leading drug candidate which is an antibiotic solution used to treat catheter-related bloodstream infections (Mino-Lok®) and is expected to be amortized on a straight-line basis over a period of eight years commencing upon revenue generation. Goodwill represents the value of LMB's industry relationships and its assembled workforce. Goodwill will not be amortized but will be tested at least annually for impairment. Citius is subject to a number of risks common to companies in the pharmaceutical industry including, but not limited to, risks related to the development by Citius or its competitors of research and development stage product candidates, market acceptance of its product candidates that might be approved, competition from larger companies, dependence on key personnel, dependence on key suppliers and strategic partners, the Company's ability to obtain additional financing and the Company's compliance with governmental and other regulations. Basis of Presentation and Summary of Significant Accounting Policies Basis of Preparation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to fairly state the condensed consolidated financial position of the Company as of December 31, 2019, the results of its operations and cash flows for the three-month periods ended December 31, 2019 and 2018, and are not necessarily indicative of the results that may be expected for the year ending September 30, 2020. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended September 30, 2019 filed with the Securities and Exchange Commission. Recently Adopted Accounting Standards In February 2016, the FASB issued Accounting Standards Update ("ASU") No. 2016-02, Leases (Topic 842). ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements. Leases will be classified as either finance leases or operating leases, with classification affecting the pattern of expense recognition in the statement of operations. In January, July and December 2018, the FASB issued ASU No's. 2018-01, 2018-10, 2018-11, 2018-20 and 2019-01, which were targeted improvements to ASU No. 2016-02 (collectively, with ASU No. 2016-02, "ASC 842") and provided entities with an additional (and optional) transition method to adopt the new lease standard, and provided clarifications to address potential narrow-scope implementation issues. The Company adopted ASU 2016-02 effective October 1, 2019 and elected the optional transition method for adoption. The Company also took advantage of the transition package of practical expedients permitted within ASU 2016-02, which among other things, allowed it to carryforward historical lease classifications. The Company also elected to keep leases with an initial term of 12 months or less off of the balance sheet as a policy election and will recognize those lease payments in the consolidated statements of operations on a straight-line basis over the lease term. As of the adoption date, the Company identified one operating lease arrangement in which it is a lessee. The adoption of this ASU resulted in the recognition of a right-of-use asset and lease liability of $1,137,724. In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting which is intended to reduce cost and complexity and to improve financial reporting for nonemployee share-based payments. The amendment is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The Company adopted ASU 2018-07 on October 1, 2019 and it did not have a material effect on the Company's financial position, results of operations or disclosures. There have been no other recently issued accounting pronouncements that have had or are expected to have a material impact on the Company's consolidated financial statements. Use of Estimates Basic and Diluted Net Loss per Common Share

Going Concern Uncertainty and M

Going Concern Uncertainty and Management's Plan	3 Months Ended
	Dec. 31, 2019
Going Concern Uncertainty and Management's Plan [Abstract]
GOING CONCERN UNCERTAINTY AND MANAGEMENT'S PLAN	2. GOING CONCERN UNCERTAINTY AND MANAGEMENT'S PLAN The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company experienced negative cash flows from operations of $5,114,260 for the three months ended December 31, 2019. The Company has generated no operating revenue to date and has principally raised capital through the issuance of debt and equity instruments to finance its operations. At December 31, 2019, the Company had a working capital deficit of $794,467. The Company estimates cash resources, including proceeds in January 2020 from the cash exercise of warrants issued in September 2019, will be sufficient to fund its operations into the third quarter of fiscal year 2020. This raises substantial doubt about the Company's ability to continue as a going concern. The Company plans to raise capital through equity financings from outside investors as well as raise additional funds from existing investors and continued borrowings under related party debt agreements. There is no assurance, however, that the Company will be successful in raising the needed capital and, if funding is available, that it will be available in amounts sufficient for and on terms acceptable to the Company. The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of the above uncertainty.

Patent and Technology License A

Patent and Technology License Agreements	3 Months Ended
	Dec. 31, 2019
Patent and Technology License Agreements [Abstract]
PATENT AND TECHNOLOGY LICENSE AGREEMENTS	3. PATENT AND TECHNOLOGY LICENSE AGREEMENTS Patent and Technology License Agreement – Mino-Lok LMB has a patent and technology license agreement with Novel Anti-Infective Therapeutics, Inc. ("NAT") to develop and commercialize Mino-Lok® on an exclusive, worldwide sub licensable basis, as amended. LMB pays an annual maintenance fee each June until commercial sales of a product subject to the license commence. The annual fee paid in June 2019 was $90,000 (at which level it will remain for as long as it is due) and the annual fee paid in June 2018 was $75,000. LMB will also pay annual royalties on net sales of licensed products, with royalties ranging from the mid-single digits to the low double digits or, in the event the licensed product is not subject to a valid patent claim, the royalty is reduced to mid- to lower-single digits. In limited circumstances in which the licensed product is not subject to a valid patent claim and a competitor is selling a competing product, the royalty rate is in the low single digits. After a commercial sale is obtained, LMB must pay minimum aggregate annual royalties of $100,000 in the first commercial year which is prorated for a less than 12-month period, increasing $25,000 per year to a maximum of $150,000 annually. LMB must also pay NAT up to $1,100,000 upon achieving specified regulatory and sales milestones. Finally, LMB must pay NAT a specified percentage of payments received from any sub licensees. Unless earlier terminated by NAT, based on the failure by the Company to achieve certain development and commercial milestones or for various breaches by the Company, the license agreement remains in effect until the date that all patents licensed under the agreement have expired and all patent applications within the licensed patent rights have been cancelled, withdrawn or expressly abandoned. Patent and Technology License Agreement – Mino-Wrap On January 2, 2019, we entered into a patent and technology license agreement with the Board of Regents of the University of Texas System on behalf of the University of Texas M. D. Anderson Cancer Center ("Licensor"), whereby we in-licensed exclusive worldwide rights to the patented technology for any and all uses relating to breast implants. We intend to develop a liquefying gel-based wrap containing minocycline and rifampin for the reduction of infections associated with breast implants following breast reconstructive surgeries ("Mino-Wrap"). We are required to use commercially reasonable efforts to commercialize Mino-Wrap under several regulatory scenarios and achieve milestones associated with these regulatory options leading to an approval from the U.S. Food and Drug Administration ("FDA"). Under the license agreement, the Company paid a nonrefundable upfront payment of $125,000 which was recorded as research and development expense during the year ended September 30, 2019. We are obligated to pay an annual maintenance fee of $30,000, commencing in January 2020, which increases annually by $15,000 per year up to a maximum of $90,000. Annual maintenance fees cease on the first sale of product. We also must pay up to an aggregate of $2.1 million in milestone payments, contingent on the achievement of various regulatory and commercial milestones. Under the terms of the license agreement, we also must pay a royalty of mid- to upper-single digit percentages of net sales, depending on the amount of annual sales, and subject to downward adjustment to lower- to mid-single digit percentages in the event there is no valid patent for the product in the United States at the time of sale. After the first sale of product, we will owe an annual minimum royalty payment of $100,000 that will increase annually by $25,000 for the duration of the term. We will be responsible for all patent expenses incurred by Licensor for the term of the agreement although Licensor is responsible for filing, prosecution and maintenance of all patents. Unless earlier terminated by Licensor, based upon the failure by us to achieve certain development and commercial milestones or for various breaches by us, the agreement expires on the later of the expiration of the patents or January 2, 2034.

Notes Payable - Related Parties

Notes Payable - Related Parties	3 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
NOTES PAYABLE - RELATED PARTIES	4. NOTES PAYABLE – RELATED PARTIES The aggregate principal balance as of December 31, 2019 consists of notes payable held by our Chairman, Leonard Mazur, in the amount of $160,470 and notes payable held by our Chief Executive Officer, Myron Holubiak, in the amount of $12,500. Notes with an aggregate principal balance of $104,000 accrue interest at the prime rate plus 1.0% per annum and notes with an aggregate principal balance of $68,970 accrue interest at 12% per annum. Interest expense on notes payable – related parties was $3,991 and $4,003, respectively, for the three months ended December 31, 2019 and 2018.

Common Stock, Stock Options and

Common Stock, Stock Options and Warrants	3 Months Ended
	Dec. 31, 2019
Stockholders' Equity Note [Abstract]
COMMON STOCK, STOCK OPTIONS AND WARRANTS	5. COMMON STOCK, STOCK OPTIONS AND WARRANTS Registered Direct/Private Placement Offerings On April 3, 2019, the Company closed a registered direct offering with several institutional and accredited investors for the sale of 3,430,421 shares of common stock at $1.545 per share for gross proceeds of $5,300,001. Simultaneously, the Company also privately sold and issued 3,430,421 immediately exercisable two-year unregistered warrants to the investors with an exercise price of $1.42 per share. The Company paid the placement agent for the offering a fee of 7% of the gross proceeds totaling $371,000 and issued the placement agent 240,130 immediately exercisable two-year warrants with an exercise price of $1.93125 per share. The Company also reimbursed the placement agent for $85,000 in expenses and incurred $10,000 in other expenses. Net proceeds from the offering were $4,834,001. The estimated fair value of the 3,430,421 warrants issued to the investors was $2,709,467 and the estimated fair value of the 240,130 warrants issued to the placement agent was $169,854. On September 27, 2019, Citius closed an underwritten at-the-market offering of (i) 6,760,615 units, each unit consisting of one share of common stock and one immediately exercisable five-year warrant to purchase one share at $0.77 per share, and (ii) 1,060,615 pre-funded units, each pre-funded unit consisting of one pre-funded warrant to purchase one share and one immediately exercisable five-year warrant to purchase one share at $0.77 per share. The pre-funded warrants included in the pre-funded units are immediately exercisable at a price of $0.0001 per share and do not expire. The offering price was $0.8951 per unit and $0.895 per pre-funded unit. The net proceeds of the offering were $6,290,335. The Company issued the underwriter immediately exercisable five-year warrants to purchase up to 547,486 shares at $1.118875 per share with an estimated fair value of $323,414. The estimated fair value of the 1,060,615 pre-funded warrants was $809,145, and the estimated fair value of the 7,821,230 warrants included in the units and the pre-funded units issued to the investors was $4,845,341. Common Stock Issued for Services On February 13, 2019, the Company issued 125,000 shares of common stock for investor relations services and expensed the $117,500 fair value of the common stock issued. On September 16, 2019, the Company issued 94,097 shares of common stock for investor relations services and expensed the $94,097 fair value of the common stock issued. On November 4, 2019, the Company issued 186,566 shares of common stock for strategic consulting and corporate development services and expensed the $100,000 fair value of the common stock issued. Stock Option Plans Pursuant to its 2014 Stock Incentive Plan (the "2014 Plan") the Company reserved 866,667 shares of common stock for issuance to employees, directors and consultants. The Board of Directors (or committees and/or executive officers delegated by the Board of Directors) may grant stock options, stock appreciation rights, restricted stock, restricted stock units, other stock-based awards and cash-based awards under the 2014 Plan. As of December 31, 2019, there were options to purchase an aggregate of 861,838 shares of common stock outstanding under the 2014 Plan, options to purchase 4,829 shares were exercised, and no shares remain available for future grants. On February 7, 2018, our stockholders approved the 2018 Omnibus Stock Incentive Plan (the "2018 Plan") and the Company reserved 2,000,000 shares of common stock for issuance to employees, directors and consultants. Pursuant to the 2018 Plan, the Board of Directors (or committees and/or executive officers delegated by the Board of Directors) may grant stock options, stock appreciation rights, restricted stock, restricted stock units, other stock-based awards and cash-based awards. As of December 31, 2019, there were options to purchase an aggregate of 1,890,000 shares of common stock outstanding under the 2018 Plan and 110,000 shares available for future grants. The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. Due to its limited operating history and limited number of sales of its common stock, the Company estimated its volatility in consideration of a number of factors including the volatility of comparable public companies through December 31, 2018. Since January 1, 2019, the Company has estimated its volatility using the trading activity of its common stock. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption. The expected term of stock options granted, all of which qualify as "plain vanilla," is based on the average of the contractual term (generally 10 years) and the vesting period. For non-employee options, the expected term is the contractual term. A summary of option activity under the 2014 Plan and 2018 Plan is presented below: Option Weighted- Weighted- Aggregate Outstanding at October 1, 2019 1,771,039 $ 4.03 Granted 980,799 0.67 Exercised — — Forfeited or expired — — Outstanding at December 31, 2019 2,751,838 $ 2.831 8.3 years $ 416,892 Exercisable at December 31, 2019 1,199,509 $ 5.18 6.9 years $ 67,461 On October 8, 2019, the Board of Directors granted stock options to purchase a total of 705,799 shares to employees, 125,000 shares to directors and 125,000 shares to consultants at $0.67 per share. On October 28, 2019, the Board of Directors granted stock options to purchase a total of 25,000 shares to a consultant at $0.55 per share. All of these options vest over terms of 12 to 36 months and have a term of 10 years. Stock-based compensation expense for the three months ended December 31, 2019 and 2018 was $220,384 and $171,249, respectively. At December 31, 2019, unrecognized total compensation cost related to unvested awards of $1,208,053 is expected to be recognized over a weighted average period of 1.9 years. Warrants As of December 31, 2019, the Company has reserved shares of common stock for the exercise of outstanding warrants. The following table summarizes the warrants outstanding: Exercise Number Expiration Dates Investor Warrants $ 9.00 202,469 March 19, 2020 – September 14, 2020 Investor Warrants 9.00 307,778 November 5, 2020 – April 25, 2021 LMB Warrants 6.15 38,771 November 20, 2020 – March 2, 2021 LMB Warrants 9.90 4,985 January 8, 2020 LMB Warrants 20.70 2,668 March 6, 2020 LMB Warrants 7.50 73,883 August 18, 2020 – March 14, 2021 LMB Warrants 7.50 53,110 March 24, 2022 – April 29, 2022 Financial Advisor Warrants 3.00 25,833 August 15, 2021 2016 Offering Warrants 4.13 140,819 November 23, 2021 – February 27, 2022 2017 Public Offering Warrants 4.13 1,622,989 August 2, 2022 2017 Public Offering Underwriter Warrants 4.54 65,940 February 2, 2023 December 2017 Registered Direct/Private Placement Offering Investor Warrants 4.63 640,180 June 19, 2023 December 2017 Registered Direct/Private Placement Offering Placement Agent Warrants 5.87 89,625 December 19, 2022 March 2018 Registered Direct/Private Placement Offering Investor Warrants 2.86 669,504 October 2, 2023 March 2018 Registered Direct/Private Placement Offering Placement Agent Warrants 3.73 46,866 March 28, 2023 August 2018 Offering Investor Warrants 1.15 7,843,138 August 14, 2023 August 2018 Offering Agent Warrants 1.59 549,020 August 8, 2023 April 2019 Registered Direct/Private Placement Offering Investor Warrants 1.42 3,430,421 April 5, 2021 April 2019 Registered Direct/Private Placement Offering Placement Agent Warrants 1.93 240,130 April 5, 2021 September 2019 Offering Investor Warrants 0.77 7,821,230 September 27, 2024 September 2019 Offering Underwriter Warrants 1.12 547,486 September 27, 2024 24,416,845 During the three months ended December 31, 2018, 1,600,000 of the August 2018 Offering Pre-Funded Unit Warrants were exercised at $0.01 per share for net proceeds of $16,000. During the three months ended December 31, 2019, 1,060,615 of the September 2019 Offering Pre-Funded Unit Warrants were exercised at $0.0001 per share for net proceeds of $106. At December 31, 2019, the weighted average remaining life of the outstanding warrants is 3.49 years, all warrants are exercisable, and the aggregate intrinsic value of the warrants outstanding was $1,955,308. Common Stock Reserved A summary of common stock reserved for future issuances as of December 31, 2019 is as follows: Stock plan options outstanding 2,751,838 Stock plan shares available for future grants 110,000 Warrants outstanding 24,416,845 Unit purchase options outstanding 201,334 Total 27,480,017

Related Party Transactions

Related Party Transactions	3 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	6. RELATED PARTY TRANSACTIONS Our Chairman of the Board, Leonard Mazur, was the cofounder and Vice Chairman of Akrimax Pharmaceuticals, LLC (“Akrimax”), a privately held pharmaceutical company specializing in producing cardiovascular and general pharmaceutical products. The Company leased office space from Akrimax through April 30, 2019 (see Note 7). The Company has outstanding debt due to Leonard Mazur (Chairman of the Board) and Myron Holubiak (Chief Executive Officer) (see Note 4). In connection with the April 2019 registered direct/private placement offering (See Note 5), Mr. Mazur purchased 1,165,048 shares of common stock at $1.545 per share and received 1,165,048 warrants with an exercise price of $1.42 per share, and Mr. Holubiak purchased 129,450 shares of common stock at $1.545 per share and received 129,450 warrants with an exercise price of $1.42 per share. The purchases were made on the same terms as for all other investors. In connection with the September 2019 offering (See Note 5), Mr. Mazur purchased 2,234,700 shares of common stock at $0.8951 per share and received 2,234,700 warrants exercisable at $0.77 per share, and Mr. Holubiak purchased 558,597 shares of common stock at $0.8951 per share and received 558,597 warrants exercisable at $0.77 per share. The purchases were made on the same terms as for all other investors.

Operating Lease

Operating Lease	3 Months Ended
	Dec. 31, 2019
Leases [Abstract]
OPERATING LEASE	7. OPERATING LEASE LMB leased office space from Akrimax (see Note 6) in Cranford, New Jersey at a monthly rental rate of $2,167 pursuant to an agreement which expired on April 30, 2019. Rent expense for the three months ended December 31, 2018 was $6,501. Effective July 1, 2019, Citius entered into a 76-month lease for office space in Cranford, NJ. As of September 30, 2019, minimum future lease payments under non-cancellable leases (consisting of the Cranford lease only) were as follows: Year Ending September 30, 2020 $ 210,557 2021 234,447 2022 239,306 2023 244,165 2024 249,024 Thereafter 275,343 Total $ 1,452,842 Citius will also pay its proportionate share of real estate taxes and operating expenses in excess of the base year expenses. These costs are considered to be variable lease payments and are not included in the determination of the lease's right-of-use asset or lease liability. The Company identified and assessed the following significant assumptions in recognizing its right-of-use assets and corresponding lease liabilities: ● As the Company's current Cranford lease does not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company has estimated its incremental borrowing rate based on electing the remaining lease term as of the adoption date. ● Since the Company elected to account for each lease component and its associated non-lease components as a single combined component, all contract consideration was allocated to the combined lease component. ● The expected lease terms include noncancelable lease periods The elements of lease expense are as follows: Lease cost Three Months Operating lease cost $ 57,349 Short-term lease cost — Variable lease cost — Total lease cost $ 57,349 Other information Weighted-average remaining lease term - operating leases 5.8 Years Weighted-average discount rate - operating leases 8.0 % Maturities of lease liabilities due under the Company's current Cranford lease as of December 31, 2019 is as follows: Leases As of 2020 (excluding the 3 months ended December 31, 2019) $ 172,494 2021 234,447 2022 239,306 2023 244,165 2024 249,024 Thereafter 275,343 Total lease payments 1,414,779 Less: interest (292,337 ) Present value of lease liabilities $ 1,122,442 Leases Classification As of Assets Lease asset Operating $ 1,103,155 Total lease assets $ 1,103,155 Liabilities Current Operating $ 146,244 Non-current Operating 976,198 Total lease liabilities $ 1,122,442 Interest expense on the lease liability was $22,780 for the three months ended December 31, 2019.

Fda Refund

Fda Refund	3 Months Ended
	Dec. 31, 2019
FDA Refund [Abstract]
FDA REFUND	8. FDA REFUND In November 2019, the Company received an additional $110,207 refund from the FDA for 2016 product and establishment fees because the fees paid by the Company exceeded the costs of the FDA's review of the associated applications. The Company recorded the $110,207 as other income during the three months ended December 31, 2019.

Subsequent Events

Subsequent Events	3 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	9. SUBSEQUENT EVENTS Nasdaq Listing On October 30, 2019, Citius had received notice from The Nasdaq Stock Market, ("NASDAQ"), indicating that, because the closing bid price for the common stock had fallen below $1.00 per share for 30 consecutive business days, the Company no longer complied with the $1.00 minimum bid price requirement for continued listing. On January 31, 2020, Citius received notice from NASDAQ stating that because the closing bid price of the Company's common stock was $1.00 per share or greater for 10 consecutive business days, the Company had regained compliance with the Listing Rule requirements of NASDAQ. Warrant Exercises In January 2020, investors who participated in the September 2019 Offering exercised 1,315,715 warrants to purchase 1,315,715 shares of common stock. The exercise price of each warrant was $0.77 per share resulting in net proceeds of $1,013,101 to the Company. Annual Meeting On February 10, 2020, the Company's stockholders approved the 2020 Omnibus Stock Incentive Plan ("2020 Stock Plan"). The 2020 Stock Plan authorizes a maximum of 3,110,000 shares. The 2020 Stock Plan provides incentives to employees, directors, and consultants of the Company in form of granting an option, SAR, dividend equivalent right, restricted stock, restricted stock unit, or other right or benefit under the 2020 Stock Plan.

Nature of Operations, Basis o_2

Nature of Operations, Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Preparation	Basis of Preparation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to fairly state the condensed consolidated financial position of the Company as of December 31, 2019, the results of its operations and cash flows for the three-month periods ended December 31, 2019 and 2018, and are not necessarily indicative of the results that may be expected for the year ending September 30, 2020. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended September 30, 2019 filed with the Securities and Exchange Commission.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards In February 2016, the FASB issued Accounting Standards Update ("ASU") No. 2016-02, Leases (Topic 842). ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements. Leases will be classified as either finance leases or operating leases, with classification affecting the pattern of expense recognition in the statement of operations. In January, July and December 2018, the FASB issued ASU No's. 2018-01, 2018-10, 2018-11, 2018-20 and 2019-01, which were targeted improvements to ASU No. 2016-02 (collectively, with ASU No. 2016-02, "ASC 842") and provided entities with an additional (and optional) transition method to adopt the new lease standard, and provided clarifications to address potential narrow-scope implementation issues. The Company adopted ASU 2016- 02 effective October 1, 2019 and elected the optional transition method for adoption. The Company also took advantage of the transition package of practical expedients permitted within ASU 2016-02, which among other things, allowed it to carryforward historical lease classifications. The Company also elected to keep leases with an initial term of 12 months or less off of the balance sheet as a policy election and will recognize those lease payments in the consolidated statements of operations on a straight-line basis over the lease term. As of the adoption date, the Company identified one operating lease arrangement in which it is a lessee. The adoption of this ASU resulted in the recognition of a right-of-use asset and lease liability of $1,137,724. In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting which is intended to reduce cost and complexity and to improve financial reporting for nonemployee share-based payments. The amendment is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The Company adopted ASU 2018-07 on October 1, 2019 and it did not have a material effect on the Company's financial position, results of operations or disclosures. There have been no other recently issued accounting pronouncements that have had or are expected to have a material impact on the Company's consolidated financial statements.
Use of Estimates	Use of Estimates
Basic and Diluted Net Loss per Common Share	Basic and Diluted Net Loss per Common Share

Common Stock, Stock Options a_2

Common Stock, Stock Options and Warrants (Tables)	3 Months Ended
	Dec. 31, 2019
Stockholders' Equity Note [Abstract]
Schedule of stock option activity	Option Weighted- Weighted- Aggregate Outstanding at October 1, 2019 1,771,039 $ 4.03 Granted 980,799 0.67 Exercised — — Forfeited or expired — — Outstanding at December 31, 2019 2,751,838 $ 2.831 8.3 years $ 416,892 Exercisable at December 31, 2019 1,199,509 $ 5.18 6.9 years $ 67,461
Schedule of warrants outstanding	Exercise Number Expiration Dates Investor Warrants $ 9.00 202,469 March 19, 2020 – September 14, 2020 Investor Warrants 9.00 307,778 November 5, 2020 – April 25, 2021 LMB Warrants 6.15 38,771 November 20, 2020 – March 2, 2021 LMB Warrants 9.90 4,985 January 8, 2020 LMB Warrants 20.70 2,668 March 6, 2020 LMB Warrants 7.50 73,883 August 18, 2020 – March 14, 2021 LMB Warrants 7.50 53,110 March 24, 2022 – April 29, 2022 Financial Advisor Warrants 3.00 25,833 August 15, 2021 2016 Offering Warrants 4.13 140,819 November 23, 2021 – February 27, 2022 2017 Public Offering Warrants 4.13 1,622,989 August 2, 2022 2017 Public Offering Underwriter Warrants 4.54 65,940 February 2, 2023 December 2017 Registered Direct/Private Placement Offering Investor Warrants 4.63 640,180 June 19, 2023 December 2017 Registered Direct/Private Placement Offering Placement Agent Warrants 5.87 89,625 December 19, 2022 March 2018 Registered Direct/Private Placement Offering Investor Warrants 2.86 669,504 October 2, 2023 March 2018 Registered Direct/Private Placement Offering Placement Agent Warrants 3.73 46,866 March 28, 2023 August 2018 Offering Investor Warrants 1.15 7,843,138 August 14, 2023 August 2018 Offering Agent Warrants 1.59 549,020 August 8, 2023 April 2019 Registered Direct/Private Placement Offering Investor Warrants 1.42 3,430,421 April 5, 2021 April 2019 Registered Direct/Private Placement Offering Placement Agent Warrants 1.93 240,130 April 5, 2021 September 2019 Offering Investor Warrants 0.77 7,821,230 September 27, 2024 September 2019 Offering Underwriter Warrants 1.12 547,486 September 27, 2024 24,416,845
Summary of common stock reserved for future issuances	Stock plan options outstanding 2,751,838 Stock plan shares available for future grants 110,000 Warrants outstanding 24,416,845 Unit purchase options outstanding 201,334 Total 27,480,017

Operating Lease (Tables)

Operating Lease (Tables)	3 Months Ended
	Dec. 31, 2019
Operating Lease
Schedule of minimum future lease payments under non-cancellable leases	Year Ending September 30, 2020 $ 210,557 2021 234,447 2022 239,306 2023 244,165 2024 249,024 Thereafter 275,343 Total $ 1,452,842
Shedule of lease expense	Lease cost Three Months Operating lease cost $ 57,349 Short-term lease cost — Variable lease cost — Total lease cost $ 57,349 Other information Weighted-average remaining lease term - operating leases 5.8 Years Weighted-average discount rate - operating leases 8.0 %
Shedule of maturities of lease liabilities due under the Company’s current Cranford lease	Leases As of 2020 (excluding the 3 months ended December 31, 2019) $ 172,494 2021 234,447 2022 239,306 2023 244,165 2024 249,024 Thereafter 275,343 Total lease payments 1,414,779 Less: interest (292,337 ) Present value of lease liabilities $ 1,122,442 Leases Classification As of Assets Lease asset Operating $ 1,103,155 Total lease assets $ 1,103,155 Liabilities Current Operating $ 146,244 Non-current Operating 976,198 Total lease liabilities $ 1,122,442

Nature of Operations, Basis o_3

Nature of Operations, Basis of Presentation and Summary of Significant Accounting Policies (Details) - USD ($)	1 Months Ended
	Mar. 30, 2016	Dec. 31, 2019	Oct. 02, 2019
Nature of Operations, Basis of Presentation and Summary of Significant Accounting Policies (Textual)
Right of use asset and lease liability		$ 1,122,442
Operating Lease Arrangement [Member]
Nature of Operations, Basis of Presentation and Summary of Significant Accounting Policies (Textual)
Right of use asset and lease liability			$ 1,137,724
Series of Individually Immaterial Business Acquisitions [Member]
Nature of Operations, Basis of Presentation and Summary of Significant Accounting Policies (Textual)
Intangible assets	$ 19,400,000
Goodwill	$ 1,586,796
Amortized on straight-line basis period	8 years

Going Concern Uncertainty and_2

Going Concern Uncertainty and Management's Plan (Details) - USD ($)	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Going Concern Uncertainty and Management's Plan (Textual)
Cash flows from operations	$ (5,114,260)	$ (2,158,530)
Working capital deficit	$ 794,467

Patent and Technology License_2

Patent and Technology License Agreements (Details) - USD ($)	Jan. 02, 2019	Dec. 31, 2019	Jun. 30, 2019	Jun. 30, 2018
Patent and Technology License Agreements (Textual)
Maintenance fee			$ 90,000	$ 75,000
Minimum aggregate annual royalties		$ 100,000
Increasing annual royalties		25,000
Maximum aggregate annual royalties		150,000
Payable amount to NAT		$ 1,100,000
Nonrefundable upfront payment	$ 125,000
Description of license agreement	We are obligated to pay an annual maintenance fee of $30,000, commencing in January 2020, that increases annually by $15,000 per year up to a maximum of $90,000.
Aggregate of milestone payments	$ 2,100,000
Annual minimum royalty payment	100,000
Increase annual payment	$ 25,000
Agreement expiration date	Jan. 2, 2034

Notes Payable - Related Parti_2

Notes Payable - Related Parties (Details) - USD ($)	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Notes Payable - Related Parties (Textual)
Interest expense on notes payable - related parties	$ 3,991	$ 4,003
Leonard Mazur [Member]
Notes Payable - Related Parties (Textual)
Principal balance	160,470
Note Payable [Member]
Notes Payable - Related Parties (Textual)
Principal balance	$ 104,000
Percentage of accrued interest	1.00%
Note Payable One [Member]
Notes Payable - Related Parties (Textual)
Principal balance	$ 68,970
Percentage of accrued interest	12.00%
Chief Executive Officer [Member]
Notes Payable - Related Parties (Textual)
Principal balance	$ 12,500

Common Stock, Stock Options a_3

Common Stock, Stock Options and Warrants (Details) - Stock Options [Member]	3 Months Ended
	Dec. 31, 2019USD ($)$ / sharesshares
Option Shares
Outstanding, beginning balance | shares	1,771,039
Granted | shares	980,799
Exercised | shares
Forfeited or expired | shares
Outstanding, ending balance | shares	2,751,838
Exercisable, ending balance | shares	1,199,509
Weighted - Average Exercise Price
Outstanding, beginning balance | $ / shares	$ 4.03
Weighted - Average Exercise Price, Granted | $ / shares	0.67
Weighted - Average Exercise Price, Exercised | $ / shares
Weighted - Average Exercise Price, Forfeited or expired | $ / shares
Weighted - Average Exercise Price, Outstanding, ending balance | $ / shares	2.831
Weighted - Average Exercise Price, Exercisable, ending balance | $ / shares	$ 5.18
Weighted-Average Remaining Contractual Term
Weighted-Average Remaining Contractual Term, ending	8 years 3 months 19 days
Weighted-average remaining contractual term, exercisable	6 years 10 months 25 days
Aggregate Intrinsic Value
Aggregate Intrinsic Value, ending balance | $	$ 416,892
Aggregate Intrinsic Value, Exercisable ending balance | $	$ 67,461

Common Stock, Stock Options a_4

Common Stock, Stock Options and Warrants (Details 1)	3 Months Ended
	Dec. 31, 2019$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number	24,416,845
Investor Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 9
Number	202,469
Expiration Dates	March 19, 2020 -September 14, 2020
Investor Warrants One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 9
Number	307,778
Expiration Dates	November 5, 2020 - April 25, 2021
LMB Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 6.15
Number	38,771
Expiration Dates	November 20, 2020 – March 2, 2021
LMB Warrants One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 9.90
Number	4,985
Expiration Dates	January 8, 2020
LMB Warrants Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 20.70
Number	2,668
Expiration Dates	March 6, 2020
LMB Warrants Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 7.50
Number	73,883
Expiration Dates	August 18, 2020 - March 14, 2021
LMB Warrants Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 7.50
Number	53,110
Expiration Dates	March 24, 2022 - April 29, 2022
Financial Advisor Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 3
Number	25,833
Expiration Dates	August 15, 2021
2016 Offering Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 4.13
Number	140,819
Expiration Dates	November 23, 2021 - February 27, 2022
2017 Public Offering Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 4.13
Number	1,622,989
Expiration Dates	August 2, 2022
2017 Public Offering Underwriter Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 4.54
Number	65,940
Expiration Dates	February 2, 2023
December 2017 Registered Direct/Private Placement Offering Investor Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 4.63
Number	640,180
Expiration Dates	June 19, 2023
December 2017 Registered Direct/Private Placement Offering Placement Agent Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 5.87
Number	89,625
Expiration Dates	December 19, 2022
March 2018 Registered Direct/Private Placement Offering Investor Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 2.86
Number	669,504
Expiration Dates	October 2, 2023
March 2018 Registered Direct/Private Placement Offering Placement Agent Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 3.73
Number	46,866
Expiration Dates	March 28, 2023
August 2018 Offering Investor Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 1.15
Number	7,843,138
Expiration Dates	August 14, 2023
August 2018 Offering Agent Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 1.59
Number	549,020
Expiration Dates	August 8, 2023
April 2019 Registered Direct/Private Placement Offering Investor Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 1.42
Number	3,430,421
Expiration Dates	April 5, 2021
April 2019 Registered Direct/Private Placement Offering Placement Agent Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 1.93
Number	240,130
Expiration Dates	April 5, 2021
September 2019 Offering Investor Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 0.77
Number	7,821,230
Expiration Dates	September 27, 2024
September 2019 Offering Underwriter Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price | $ / shares	$ 1.12
Number	547,486
Expiration Dates	September 27, 2024

Common Stock, Stock Options a_5

Common Stock, Stock Options and Warrants (Details 2)	3 Months Ended
	Dec. 31, 2019shares
Stockholders' Equity Note [Abstract]
Stock plan options outstanding	2,751,838
Stock plan shares available for future grants	110,000
Warrants outstanding	24,416,845
Unit purchase options outstanding	201,334
Total	27,480,017

Common Stock, Stock Options a_6

Common Stock, Stock Options and Warrants (Details Textual) - USD ($)	Oct. 08, 2019	Apr. 03, 2019	Nov. 04, 2019	Oct. 28, 2019	Sep. 27, 2019	Sep. 16, 2019	Feb. 13, 2019	Dec. 31, 2019	Dec. 31, 2018	Sep. 30, 2019	Feb. 07, 2018
Common Stock, Stock Options and Warrants (Textual)
Sale of stock price					$ 0.895
Proceeds from common stock warrant exercises								$ 106	$ 16,000
Common stock, shares issued								30,177,674		28,930,493
Stock option purchase grants								110,000
Stock-based compensation expense								$ 220,384	$ 171,249
Unrecognized total compensation cost related to unvested awards								$ 1,208,053
Board of Directors [Member]
Common Stock, Stock Options and Warrants (Textual)
Shares per unit price	$ 0.67			$ 0.55
Stock options to purchase exercised	705,799			25,000
Stock option purchase grants	125,000
Shares to directors	125,000
Options vest over terms, description				All of these options vest over terms of 12 to 36 months and have a term of 10 years
Common Stock [Member]
Common Stock, Stock Options and Warrants (Textual)
Common stock, par value					0.0001
Shares per unit price					$ 0.77
Warrants to purchase common stock					547,486
Estimated fair value of the warrant granted to the placement agent					$ 323,414
Sale of stock price					$ 0.8951
Warrants sold and issued to investors					$ 6,290,335
Exercise price of warrants					$ 1.118875
Common stock issued for services			186,566			94,097	125,000
Common stock issued for services fair value			$ 100,000			$ 94,097	$ 117,500
Description of warrants					The estimated fair value of the 1,060,615 pre-funded warrants was $809,145, and the estimated fair value of the 7,821,230 warrants included in the units and the pre-funded units issued to the investors was $4,845,341.
Offering, Description					(i) 6,760,615 units, each unit consisting of one share of common stock and one immediately exercisable five-year warrant to purchase one share at $0.77 per share, and (ii) 1,060,615 pre-funded units
Retained Earnings [Member]
Common Stock, Stock Options and Warrants (Textual)
Recognized over weighted average period								3 years 5 months 27 days
Warrant [Member]
Common Stock, Stock Options and Warrants (Textual)
Warrants sold and issued to investors								$ 1,315,715
Exercise price of warrants								$ 0.77
Stock options to purchase exercised								1,013,101
Aggregate intrinsic value for the warrants outstanding								$ 1,955,308
Recognized over weighted average period								1 year 10 months 25 days
2018 Public Offering [Member]
Common Stock, Stock Options and Warrants (Textual)
Common stock exercise price per share								$ 0.0001	$ 0.01
Number of units sold								1,060,615	1,600,000
Number of units sold for gross proceeds								$ 106	$ 16,000
Registered Direct And Private Placement Offering [Member] | Investor [Member]
Common Stock, Stock Options and Warrants (Textual)
Other cash expenses related to placements		$ 85,000
Sale of common stock		3,430,421
Warrants sold and issued to investors		$ 2,709,467
Proceeds from common stock warrant exercises		4,834,001
Other expense		$ 10,000
Registered Direct And Private Placement Offering [Member] | Placement Agent [Member]
Common Stock, Stock Options and Warrants (Textual)
Sale of common stock		3,430,421
Sale of stock price		$ 1.545
Warrants sold and issued to investors		$ 169,854
Warrants issued		240,130
Description of warrants		The Company paid the placement agent for the offering a fee of 7% of the gross proceeds totaling $371,000 and issued the placement agent 240,130 immediately exercisable two-year warrants with an exercise price of $1.93125 per share.
Registered Direct And Private Placement Offering [Member] | Accredited Investors [Member]
Common Stock, Stock Options and Warrants (Textual)
Sale of stock price		$ 1.42
Warrants sold and issued to investors		$ 5,300,001
Stock Options [Member]
Common Stock, Stock Options and Warrants (Textual)
Warrants to purchase common stock								861,838
Weighted average period								10 years
Common stock, shares issued								866,667
Common stock outstanding								2,751,838		1,771,039
Stock options to purchase exercised
Stock option purchase grants
Financial advisor warrants were exercised								4,829
Aggregate intrinsic value for the warrants outstanding								$ 67,461
Omnibus Stock Incentive Plan [Member]
Common Stock, Stock Options and Warrants (Textual)
Common stock, shares issued											2,000,000
Common stock outstanding								1,890,000
Stock option purchase grants								110,000

Related Party Transactions (Det

Related Party Transactions (Details) - $ / shares	1 Months Ended
	Sep. 30, 2019	Apr. 30, 2019
Mr. Holubiak [Member]
Related Party Transactions (Textual)
Purchase shares of common stock	558,597
Shares per unit price	$ 0.8951
Warrants share and received	558,597
Warrants with an exercise price	$ 0.77
Mr. Holubiak [Member] | Private Placement [Member]
Related Party Transactions (Textual)
Purchase shares of common stock		129,450
Shares per unit price		$ 1.545
Warrants share and received		129,450
Warrants with an exercise price		$ 1.42
Mr Mazur [Member]
Related Party Transactions (Textual)
Purchase shares of common stock		1,165,048
Shares per unit price		$ 1.545
Warrants share and received		1,165,048
Warrants with an exercise price		$ 1.42
Mr Mazur [Member] | Private Placement [Member]
Related Party Transactions (Textual)
Purchase shares of common stock	2,234,700
Shares per unit price	$ 0.8951
Warrants share and received	2,234,700
Warrants with an exercise price	$ 0.77

Operating Lease (Details)

Operating Lease (Details) - Non Cancellable Leases [Member]	Sep. 30, 2019USD ($)
2020	$ 210,557
2021	234,447
2022	239,306
2023	244,165
2024	249,024
Thereafter	275,343
Total	$ 1,452,842

Operating Lease (Details 1)

Operating Lease (Details 1)	3 Months Ended
	Dec. 31, 2019USD ($)
Lease cost
Operating lease cost	$ 57,349
Short-term lease cost
Variable lease cost
Total lease cost	$ 57,349
Other information
Weighted-average remaining lease term - operating leases	5 years 9 months 18 days
Weighted-average discount rate - operating leases	8.00%

Operating Lease (Details 2)

Operating Lease (Details 2) - Cranford Lease [Member]	3 Months Ended
	Dec. 31, 2019USD ($)
2020	$ 172,494
2021	234,447
2022	239,306
2023	244,165
2024	249,024
Thereafter	275,343
Total lease payments	1,414,779
Less: interest	(292,337)
Present value of lease liabilities	$ 1,122,442

Operating Lease (Details 3)

Operating Lease (Details 3) - USD ($)	Dec. 31, 2019	Sep. 30, 2019
Assets
Lease asset	$ 1,103,155
Total lease assets	1,103,155
Liabilities
Current	146,244
Non-current	976,198
Total lease liabilities	$ 1,122,442

Operating Lease (Details Textua

Operating Lease (Details Textual) - USD ($)	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Operating Lease (Textual)
Monthly rental rate	$ 2,167
Lease agreement expire date	Apr. 30, 2019
Rent expense		$ 6,501
Interest expense	$ 22,780

Fda Refund (Details)

Fda Refund (Details) - USD ($)	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Fda Refund (Textual)
Additional refund amount	$ 110,207
Other income	$ 110,207

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	3 Months Ended
	Dec. 31, 2019	Feb. 10, 2020
Subsequent Events (Textual)
Nasdaq Listing, description	On October 30, 2019, Citius had received notice from The Nasdaq Stock Market, (“NASDAQ”), indicating that, because the closing bid price for the common stock had fallen below $1.00 per share for 30 consecutive business days, the Company no longer complied with the $1.00 minimum bid price requirement for continued listing. On January 31, 2020, Citius received notice from NASDAQ stating that because the closing bid price of the Company’s common stock was $1.00 per share or greater for 10 consecutive business days, the Company had regained compliance with the Listing Rule requirements of NASDAQ.
Subsequent Event [Member]
Subsequent Events (Textual)
Stock authorizes		3,110,000
Stock Additional		$ 135,000
Warrant [Member]
Subsequent Events (Textual)
Stock issued Offering exercised	$ 1,315,715
Stock issued per share net proceeds	1,013,101
Stock warrants issued exercise price	$ 0.77
Stock warrants purchase	$ 1,315,715